Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Entecavir dispersible tablets (virizine)

This product is suitable for the treatment of chronic adult hepatitis B with active virus replication, continuous increase of serum transaminase ALT or active liver histology. More role
App download minus 10 yuan
Common name:
Entecavir dispersible tablets
Product No.:
S14200013734
Approval No.:
Gyzz h20100141 (inquired by the State Drug Administration)
Jianke price:
¥90.00
Product specification:
0.5mg*7s 0.5mg*14s 0.5mg*7s
Manufacturer:
Jiangxi Qingfeng Pharmaceutical Co., Ltd
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Entecavir dispersible tablets (virizine)
Main raw materials Entecavir.
Main role This product is suitable for the treatment of chronic adult hepatitis B with active virus replication, continuous increase of serum transaminase ALT or active liver histology.
Product specification 0.5mg*7s
Usage and dosage Patients should take this product under the guidance of an experienced doctor. Recommended dose: adults and adolescents aged 16 and over take this product orally, once a day, 0.5mg each time. Patients with viremia or lamivudine resistant mutation during lamivudine treatment were 1mg (0.5mg two tablets) once a day. This product should be taken on an empty stomach (at least 2 hours before or after meals). This product can be swallowed or dispersed by adding water, or the dispersible tablets can be sucked in the mouth. (see instructions for details)
manufacturing enterprise Jiangxi Qingfeng Pharmaceutical Co., Ltd
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Entecavir dispersible tablets (virizine)

[common name] Entecavir dispersible tablets

[specification and model] 0.5mg*7s

[manufacturer] Jiangxi Qingfeng Pharmaceutical Co., Ltd

[drug type] Western medicine

[approval No.] Gyzz h20100141

[validity period] 36 months

[functional indications] This product is suitable for the treatment of chronic adult hepatitis B with active virus replication, continuous increase of serum transaminase ALT or active liver histology.

[usage and dosage] Patients should take this product under the guidance of an experienced doctor. Recommended dose: adults and adolescents aged 16 and over take this product orally, once a day, 0.5mg each time. Patients with viremia or lamivudine resistant mutation during lamivudine treatment were 1mg (0.5mg two tablets) once a day. This product should be taken on an empty stomach (at least 2 hours before or after meals). This product can be swallowed or dispersed by adding water, or the dispersible tablets can be sucked in the mouth. (see instructions for details)

[adverse reactions] In studies conducted abroad, the most common adverse events of this product are headache, fatigue, dizziness and nausea. The common adverse events of patients treated with lamivudine were headache, fatigue and vertigo. In these four studies, 1% of patients treated with entecavir and 4% of patients treated with lamivudine withdrew from the study due to adverse events and abnormal laboratory test indicators, respectively.

[precautions] 1. The patient should take entecavir under the guidance of the doctor, and inform the doctor of any new symptoms and drug combination. 2. Patients should be informed that liver disease will worsen sometimes after drug withdrawal, so the treatment method should be changed under the guidance of doctors. 3. Entecavir treatment can not reduce the risk of HBV transmission through sexual contact or contaminated blood sources. Therefore, appropriate protective measures need to be taken, and liver function should be tested regularly during drug administration. Please read the instructions carefully and follow the doctor's advice.

[taboo] It is forbidden to be allergic to any ingredient in entecavir live preparation.

[listing Permit Holder] Jiangxi Qingfeng Pharmaceutical Co., Ltd

[packaging unit] box

[main ingredients] Entecavir.

[character] This product is white or off white.

[applicable population] unlimited

[medication for pregnant and lactating women] 1. The study on the effect of entecavir on pregnant women is insufficient. This product can only be used after fully weighing the potential risks and benefits of the fetus. 2. At present, there is no data suggesting that this product can affect the mother to child transmission of HBV. Therefore, appropriate intervention measures should be taken to prevent neonatal infection with HBV. 3. Entecavir can be secreted from rat milk. However, it is still unclear whether there is secretion in human milk, so mothers taking this product are not recommended to breastfeed.

[medication for children] Data on the safety and efficacy of this product for children under the age of 16 have not been established.

[medication for elderly patients] Since there are not enough elderly patients aged 65 and over to participate in the clinical study of this product, it is unclear how the response of elderly patients and young patients to this product is different. Other clinical trial reports also did not find the difference between elderly patients and young patients. Entecavir is mainly excreted by the kidney. In patients with renal function injury, the risk of toxic reaction may be higher. Because most of the elderly patients have decreased renal function, we should pay attention to the choice of drug dose and monitor renal function.

[storage] Seal and store in a dry place.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Entecavir dispersible tablets (virizine)

    ¥90.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!